Humira denied by insurance? How to appeal
The short answer
Many Humira denials now happen because the plan prefers a biosimilar version of adalimumab, the same medicine made by another company. If you can switch, the fastest route is to ask your doctor to prescribe the preferred biosimilar. If you cannot, because of a documented reaction or a failed trial, ask for a formulary exception with records. If the denial says you did not meet the medical criteria, an appeal with the right history is worth filing.
- StartThe denial letterFind what was denied, the reason, and the deadline to appeal.
- Step 1Appeal to your planMost plans give you 60 to 180 days to ask. The plan reviews its own decision.
- Step 2Go outside the planIf it says no again, someone outside the plan can decide: an independent reviewer, a hearing, or a federal office.
Can’t wait? If waiting could seriously harm your health, ask for a fast appeal. Most plans must decide within 72 hours.
What Humira is approved for
Humira (adalimumab) is a TNF blocker. As of November 2026 its FDA label lists nine uses, including moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. Some apply to children; check the label for the age for your condition.
Several companies now sell adalimumab biosimilars, such as Hyrimoz, Cyltezo, Simlandi and Hadlima. One insurer's policy describes them as having no clinically meaningful differences in safety and effectiveness from Humira.
Why plans deny Humira
The plan prefers a biosimilar. On April 1, 2024, CVS Caremark removed Humira from its major national commercial template formularies and put biosimilars in the preferred spot. One insurer's national formulary policy, reviewed in July 2026, lists Humira as non-preferred and directs the patient to try the preferred products first: adalimumab-adbm, adalimumab-adaz and Simlandi.
Prior-authorization criteria were not met. Even preferred versions need approval. That same policy says every adalimumab product, preferred or not, must meet the plan's standard prior-authorization rules, which usually ask for a specialist prescriber and, for some conditions, a trial of an older drug such as methotrexate.
The renewal lacked proof of response. Plans often reapprove only when records show the drug is working.
See step therapy denials and CVS Caremark appeals.
What your doctor's letter should document
Ask for a letter of medical necessity or a formulary exception letter that includes:
- The diagnosis, its diagnosis code, and how active the disease is, with any scores the criteria mention.
- Every prior drug, including methotrexate or other conventional drugs, with doses, start and stop dates, and results.
- Each biosimilar tried, with dates and what happened. Name the specific reaction and when it occurred.
- The specialist's role in your care.
- For renewals, specific signs the drug is working.
Plans accept chart notes, prescription claims records and pharmacy receipts as proof of past trials.
Ask the plan for the written criteria it used. Job-based plans must name the specific plan provision behind a denial and give you a free copy of any criteria they relied on. File the internal appeal within 180 days of the denial.
If Humira is not on the drug list, ask for a formulary exception instead of, or alongside, the appeal. Your doctor generally confirms that covered drugs have not worked, will not work as well, or are likely to cause harm. Individual and small-group plans must decide a standard request within 72 hours and an expedited one within 24 hours, and a denial can go to an independent reviewer. See formulary exception letters.
If the plan upholds a denial that turned on medical judgment, you can ask for external review within 4 months of the final decision. Your insurer has to accept the reviewer’s decision.
Medicare, Medicaid and manufacturer help
With a Medicare drug plan, ask for a coverage determination or exception. Your prescriber must provide a statement explaining the medical reason. The plan must decide within 72 hours, or 24 hours if expedited, and Part D exceptions can also cover step therapy and dose limits. You have 65 days to appeal a denial. See Part D appeals.
State Medicaid programs may require prior authorization for any covered drug. See Medicaid appeals.
AbbVie offers a Humira Complete Savings Card for eligible patients with commercial insurance.
Questions people ask
Why won't my insurance cover Humira anymore?
Most often because the plan now prefers an adalimumab biosimilar. CVS Caremark removed Humira from its major commercial template formularies in 2024, and other plans list Humira as non-preferred.
Is a Humira biosimilar the same drug?
It has the same active ingredient, adalimumab. One insurer's policy describes the biosimilars as having no clinically meaningful differences in safety and effectiveness, with minor differences in inactive ingredients allowed.
How do I get an exception for brand-name Humira?
Your doctor documents that you tried the preferred versions and could not continue, such as a reaction to an inactive ingredient. Send dated records. See formulary exception letters.
Insurance stopped covering Humira after I'd been on it. What can I do?
First find out why: a lapsed prior authorization, a renewal that asked for proof the drug is working, or a drug-list change. Ask your doctor to resubmit with current records. In individual and small-group plans, being in the middle of a course of treatment on a non-formulary drug qualifies for a 24-hour expedited exception. Medicare drug plans must offer a temporary supply in the first 90 days under a new plan, and that process also covers current enrollees affected by formulary changes.
What if my Humira appeal is denied?
If the denial turned on medical judgment, you can ask for external review by an independent reviewer within 4 months of the plan's final decision. A denied formulary exception in an individual or small-group plan can also go to independent review. With Medicare Part D, if the plan upholds its denial you have 60 days to ask a Part D Independent Review Entity to reconsider; see Part D appeals.
Sources
- National Library of Medicine (DailyMed): HUMIRA (adalimumab) prescribing information (DailyMed)
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for
- CVS Caremark: Bold biosimilars strategy nets success
On April 1, 2024, CVS Caremark removed Humira from our major national commercial template formularies, placing biosimilars including Hyrimoz in a preferred position.
- Cigna Healthcare: Inflammatory Conditions – Adalimumab Products Preferred Specialty Management Policy (Cigna National Formulary, review date 07/29/2026)
This program also directs the patient to try the Preferred Product(s) prior to the approval of a Non-Preferred Product.
- eCFR (Office of the Federal Register): 29 CFR 2560.503-1 -- Claims procedure
Reference to the specific plan provisions on which the determination is based
- HealthCare.gov: Internal appeals
You must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied.
- HealthCare.gov: Getting prescription medications
All other drugs covered by the plan haven’t been or won’t be as effective as the drug you’re asking for
- eCFR (Office of the Federal Register): 45 CFR 156.122 -- Prescription drug benefits
A health plan must make its determination on a standard exception and notify the enrollee or the enrollee's designee and the prescribing physician (or other prescriber, as appropriate) of its coverage determination no later than 72 hours following receipt of the request.
- HealthCare.gov: External Review
You must file a written request for an external review within 4 months after the date you receive a notice or final determination from your insurer that your claim has been denied.
- Medicare.gov: Appeals in a Medicare drug plan
If you're asking for an exception, your prescriber must provide a statement explaining the medical reason why the exception should be approved.
- eCFR (Office of the Federal Register): 42 CFR 423.568 -- Standard timeframe and notice requirements for coverage determinations
but no later than 72 hours after receipt of the physician's or other prescriber's supporting statement
- eCFR (Office of the Federal Register): 42 CFR 423.572 -- Timeframes and notice requirements for expedited coverage determinations
but no later than 24 hours after receipt of the physician's or other prescriber's supporting statement
- eCFR (Office of the Federal Register): 42 CFR 423.578 -- Exceptions process
An exception to a plan's coverage policy that causes a Part D prescription drug not to be covered because of cost utilization tools, such as a requirement for step therapy, dosage limitations, or therapeutic substitution.
- Legal Information Institute, Cornell Law School: 42 U.S. Code § 1396r-8 - Payment for covered outpatient drugs
A State may subject to prior authorization any covered outpatient drug
- AbbVie: Ways to Save | HUMIRA
The HUMIRA Complete Savings Card could help eligible, commercially insured patients save on the cost of HUMIRA.
- eCFR (Office of the Federal Register): 42 CFR 423.120 -- Access to covered Part D drugs
Ensure access to a temporary supply of drugs within the first 90 days of coverage under a new plan.
This page is general information about appeal rules in the United States. It is not legal or medical advice. Rules can change, and your plan’s documents and your denial letter control the dates that apply to you.